RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
BUY

Pfizer Inc(PFE)

Oct 27, 2004
Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$29.04

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TOP PICK

Pfizer Inc(PFE)

Oct 26, 2004
30% discount between their model price and current stock price.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 22, 2004
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Photo of Robert StovallRobert Stovall
Owned
Unlock Rating
$27.74

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 20, 2004
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$28.30

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 12, 2004
Has dropped in sympathy with Merk and their recall of Vioxx as they have a similar product which is a big seller. Pharmaceutical industry as a whole has been hurt by generics and lagging R&D. Could drop further. All money is made in the US.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$29.86

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 07, 2004
Thinks its been oversold. Big pharmas have been in the dog house for at least 5 years.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$29.99

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 01, 2004
Interested in companies that have very good earnings growth and visibility. Have a pipeline that is not being valued appropriately.
Photo of Mary FarrellMary Farrell
Owned
Unlock Rating
$30.97

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2004
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$29.66

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 13, 2004
(A Top Pick Dec 29/03. Down 9%.) Have bought more on the dips. Health care industry in the US has suffered for the last 2 years. Showing strong revenue growth.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$32.13

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 10, 2004
A lot of drug stocks have been under pressure. All of the US drug companies are in a favorable position of having reasonable growth prospects.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$31.86

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 08, 2004
Feels the US drug companies will continue to have tough sledding because of generics. This company is better equipped to fight that. Growth through acquisition.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$32.77

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 03, 2004
Best U.S. drug company. They have new products that were just introduced. Own Lipridor, the largest drug.
Photo of Jackee PrattJackee Pratt
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Aug 30, 2004
Long-term: it is a good investment.
Photo of John ZechnerJohn ZechnerUnlock Rating
$32.46

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 25, 2004
A lot of the US drug stocks got ahead of themselves for the last couple of years. Actually looks pretty good now. At about 20X earnings now.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$31.91

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 24, 2004
This is one of those stocks which everyone loves. This means everyone owns it, which concludes no one will buy any more. It is in a negative trend.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$31.53

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 706 to 720 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica